Infliximab (review) and adalimumab for the treatment of Crohn's disease

NICE technology appraisals [TA187] Published date:

This guidance updates and replaces NICE technology appraisal guidance 40 (published in April 2002).

The review and re-appraisal of infliximab for the treatment of severe active or active fistulising Crohn’s disease has resulted in a change in the guidance. Specifically, infliximab should now be given as a planned course of treatment until treatment failure (including the need for surgery) or for 12 months, whichever is shorter. Treatment should then only be continued if there is clear evidence of ongoing active disease. Adalimumab is now also recommended as another treatment option for people with severe active Crohn’s disease.

Get involved